131 related articles for article (PubMed ID: 4079282)
1. Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation.
Zekorn C; Achtert G; Hausleiter HJ; Moon CH; Eichelbaum M
Klin Wochenschr; 1985 Nov; 63(22):1180-6. PubMed ID: 4079282
[TBL] [Abstract][Full Text] [Related]
2. The relationship between paroxetine and the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF; Hallas J; Skjelbo E; Allen A; Allen GD; Cooper SM; Mellows G; Tasker TC
Clin Pharmacol Ther; 1992 Mar; 51(3):278-87. PubMed ID: 1531950
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics and biotransformation of N-propylajmaline hydrogen tartrate in man].
Hausleiter HJ; Achtert G; Khan MA; Kukovetz WR; Beubler E
Eur J Drug Metab Pharmacokinet; 1982; 7(4):329-39. PubMed ID: 7166185
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF
Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
[TBL] [Abstract][Full Text] [Related]
6. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
[TBL] [Abstract][Full Text] [Related]
7. Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma.
Paar WD; Schuhler H; Fimmers R; Dengler HJ
Eur J Clin Pharmacol; 1989; 36(6):555-60. PubMed ID: 2590312
[TBL] [Abstract][Full Text] [Related]
8. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
9. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
Skjelbo E; Brøsen K; Hallas J; Gram LF
Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
[TBL] [Abstract][Full Text] [Related]
10. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
Eichelbaum M; Bertilsson L; Säwe J
Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
[TBL] [Abstract][Full Text] [Related]
11. Influence of the defective metabolism of sparteine on its pharmacokinetics.
Eichelbaum M; Spannbrucker N; Dengler HJ
Eur J Clin Pharmacol; 1979 Sep; 16(3):189-94. PubMed ID: 499319
[TBL] [Abstract][Full Text] [Related]
12. Metabolic disposition of ajmaline.
Köppel C; Tenczer J; Arndt I
Eur J Drug Metab Pharmacokinet; 1989; 14(4):309-16. PubMed ID: 2633926
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
14. Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism.
Dahlqvist R; Bertilsson L; Birkett DJ; Eichelbaum M; Säwe J; Sjöqvist F
Clin Pharmacol Ther; 1984 Jun; 35(6):815-21. PubMed ID: 6734034
[TBL] [Abstract][Full Text] [Related]
15. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
Brøsen K; Davidsen F; Gram LF
Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418
[TBL] [Abstract][Full Text] [Related]
16. Evidence for polymorphic oxidation of sparteine in Japanese subjects.
Ishizaki T; Eichelbaum M; Horai Y; Hashimoto K; Chiba K; Dengler HJ
Br J Clin Pharmacol; 1987 Apr; 23(4):482-5. PubMed ID: 3580254
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.
Mikus G; Ha HR; Vozeh S; Zekorn C; Follath F; Eichelbaum M
Eur J Clin Pharmacol; 1986; 31(1):69-72. PubMed ID: 3780830
[TBL] [Abstract][Full Text] [Related]
18. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.
Fjordside L; Jeppesen U; Eap CB; Powell K; Baumann P; Brøsen K
Pharmacogenetics; 1999 Feb; 9(1):55-60. PubMed ID: 10208643
[TBL] [Abstract][Full Text] [Related]
19. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
Nielsen KK; Brøsen K; Hansen MG; Gram LF
Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
[TBL] [Abstract][Full Text] [Related]
20. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]